When a person is faced with cancer, they have to figure out which treatment option is best for them. Dr. David Samadi is someone who is there for those who are faced with prostate cancer, and he is someone who has come up with a new way of dealing with that type of cancer. He has developed a new way of helping men who are faced with prostate cancer. In an interview that was done with him, this doctor shared that he detects and treats those men who are facing prostate cancer and that he does that with a new robotic form of surgery.
There are times when a person becomes frustrated with the path that they are on and considers moving on to other things. Dr. David Samadi was asked in an interview if there was ever a time when he had doubts about what he was doing. He shared that there was a period of time where he was frustrated with the things that he had to deal with in pursuing Dr. David Samadi’s career but that he has learned to go with the flow now. He had been upset with the slow way in which things were moving along, but he is okay with that now.
When he was asked about how he markets what he has to offer to the men who are out there and in need of his help, Dr. David Samadi shared that relies on referrals. When he helps someone, he knows that they will go out and tell others about the work that he has done for them and the way that he has changed their life. Because he works in a way that is unique, there are people who hear about him through their friends and then come to him to see if he can help them in a way that stands above the kind of care they would receive from other doctors.
Dr. David Samadi was given the chance to share one of his greatest accomplishments when he was interviewed, and he shared information about a procedure that he has created. The way that he works in a man’s body helps to cut down on the side effects that the man must face. He is happy to help men in such a way.
Dr. David Samadi Social Media: www.linkedin.com/in/davidsamadi
To help people learn more regarding their options for cancer treatment, the CTCA, or Cancer Treatment Centers of America have joined in a partnership with WebMD. They will be providing necessary information to aid their patients, their family, and their friends successfully navigate through the journey of cancer. This includes the processes of diagnosis and treatment along with the support from the caregiver and survivorship.The CTCA is fighting cancer using two separate levels. They begin by using advanced options and cutting-edge technologies to fight the disease. These options include chemotherapy, immunotherapy, radiation and surgery. During this process, experienced clinicians in caring for cancer patients provide supportive, informed and evidence based therapies.
This enables their patients to manage any side effects including nausea, pain and fatigue.This integrative approach has been designed to enable cancer patients to better maintain their quality of life, stamina and strength. The approach allows the patients the enjoy their lives more while undergoing treatment. The environment at CTA is welcoming, and the comprehensive cancer care center is all beneath the same roof. The cancer experts are empowered, and have made a commitment to help their patients make decisions regarding their care that are extremely well informed.
When a patient approaches the CTCA for a second opinion, they often discover treatment options they were unaware of in relation to the stage and type of cancer they are fighting. Sometimes they discover they are using the right approach to treatment. The CTCA helps people understand their options for treating cancer to ensure they have confidence in the care they are receiving.The CTCA cancer experts understand that every case of cancer is different. For this reason, their approach is individualized. Their team includes specialists who have been board-certified, and have the expertise and training necessary to treat specific types of cancer.
Tempus is a technology company that is working to use modern technology in the fight against disease. Co-founded by Eric Lefkofsky, this is a company that is hoping to use the data that is gained from one patient to help the next patient. This company is one that understands the advancements that are being made and that uses them in the work that they do. Tempus has a mission to change the way that clinical data is used. They would like to provide physicians with the kind of help that they need to better treat the patients who come to see them and learn more about Eric.
Eric Lefkofsky is the son of a structural engineer father and a schoolteacher mother, and he graduated from Southfield-Lathrup High School in 1987. After receiving his high school education, he went on to study at the University of Michigan. He graduated from the University of Michigan in 1991, with honors. Following the schooling that he received at the University of Michigan, he went on to continue his education. Eager to learn more, he studied at the University of Michigan Law School. Through attending the law school, he received his Juris Doctor in 1993 and more information click here.
Giving is something that Eric Lefkofsky is passionate about, and he and his wife founded the Lefkofsky Foundation together to help those who need their assistance. This trust fund is something that was put together to be of support to a variety of causes around the world, with a focus on children. In addition to the foundation that he formed with his wife, Eric Lefkofsky also joined The Giving Pledge in 2013. This campaign is a helpful one that allows wealthy individuals like him to help others. He has given much of his money to the good of others in hopes of helping those in need.
More Visit: http://chicago.curbed.com/2015/1/6/10005148/groupon-ceo-eric-lefkofsky-the-man-behind-195m-home-sale
Seattle Genetics is an internationally recognized company that has specialized in developing targeted cancer cures. The firm’s founder is called Clay Siegall, and he has been its chairman for the past two decades that it has been in business. Seattle Genetics has impacted the pharmaceuticals industry positively by making inventions that have transformed cancer treatment. The biotechnology firm was the first to develop a technology that is called antibody-drug conjugates (ADCs). This formula has been used in manufacturing effective cancer drugs that have less harm to patients compared to chemotherapies.
Siegall has led the company and its technicians in using the ADC technology to develop drugs such as GlaxoSmithKline, Pfizer, AbbVie, and Roche. It has managed to get FDA-approval for these cures, and has commercialized them in the United States and overseas. Clay has served as a biotechnology researcher for the past three decades. Before founding Seattle Genetics, he served organizations such as the National Institute of Health and the Bristol-Myers Squibb Pharmaceutical Research Institute. Siegall’s expertise also enabled him to be appointed to the boards of companies such as BioPharmaceuticals, Ultragenyx, and Mirna Therapeutics. He holds bachelor’s degree and a Ph.D. in zoology and genetics respectively.
The research work of Seattle Genetic has significantly improved cancer treatment across the world. Its success has facilitated the growth of Clay Siegall’s career and also earned him a lot of respect in the pharmaceuticals industry. In 2013, the researcher was appointed by Mirna Therapeutics to act as its external board member. He served as an advisor to the company on matters that dealt with the development of therapeutics that are based on micro-RNA. Siegall has invented several new products at Seattle Genetics, and he has 15 patents. The researcher has also published a couple of biotechnology-based books.
The commercialization of ADC drugs has facilitated the growth of Seattle Genetics. Over 21 drugs have been manufactured by using the technology. The biotechnology firm as earned more than $675 as revenue from selling cancer medicines in the United States and abroad. It has mobilized its researchers to focus on developing personalized treatments for the life-threatening disease.